In the most recent fiscal year, Kerasal Nail recorded its third consecutive year of double-digit growth in the US and in 2018 became ranked as the No. 1 individual product in the nail fungus segment as well as in the entire foot care category, according to Moberg.
According to Moberg, the OTC-business generated sales of approximately $46.7 million in 2018.
The sale of the OTC unit will provide funding for development and commercialization of a product in Moberg’s pipeline called MOB-015, which the firm also announced it will commercialize with Bayer AG through a licensing deal.
RoundTable Healthcare Partners’ portfolio includes physician-dispensed Revision Skincare and Goodier Cosmetics, injectables and more.